During this segment, the managed care stakeholders discuss drug spending in oncology and its relation to overall costs of cancer care. Additionally, they consider which stakeholders should work with pharmaceutical companies during the early stages of drug development, and to what degree stakeholders should collaborate with pharma.
Despite their high costs, newly emerging oncology drugs make up only 20% to 25% of overall oncology spend, and certain treatments may be associated with savings when total costs of care are considered, notes Brian Kiss, MD. For instance, some treatment options are associated with reduced length of hospitalization. However, Michael Kolodziej, MD, says that within his organization, data have demonstrated that this percentage is 35%.
Dr Kolodziej explores the impact of new, high-cost agents such as PD-1/PD-L1 drugs as treatment options for different types of cancer and discusses treatment effectiveness and appropriate drug pricing.
The use of contracting may result in innovation in terms of payment for drugs, comments Scott Gottlieb, MD. On the other hand, current government regulations stifle this innovation.
Continuing the discussion, Bruce Feinberg, DO, asks Dr Gottlieb to consider which stakeholders should work with pharmaceutical companies during the early stages of drug development.
Currently, large pharmaceutical companies are working alongside payers during the development of new drugs by providing information needed to make coverage decisions, notes Dr Gottlieb. Although discussions with payers are important, he adds, pharmaceutical companies should also work with consolidated delivery systems during drug development.
Can Medicare Sustain Widespread Access to GLP-1 Therapies?
April 25th 2025Expanding Medicare coverage for glucagon-like peptide 1 (GLP-1) receptor agonists could significantly reduce obesity-related health issues, but it also risks adding tens of billions in new costs, highlighting the need for smart policy strategies to ensure access, affordability, and long-term sustainability.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Science at AACR Aims to Overcome Cancer Care Barriers
April 24th 2025A program cochair said the agenda was designed to get attendees "out of their comfort zone." The Amercian Association for Cancer Research annual meeting runs April 25-30, with the key presentations coming Sunday through Tuesday.
Read More
Top Pharmacy Leaders to Convene at Asembia’s AXS25 Summit in Las Vegas
April 24th 2025Asembia's AXS25 Summit will unite more than 8000 key decision-makers to explore pharmacy innovation, artificial intelligence, policy, and patient care from April 27 to May 1 at Wynn & Encore in Las Vegas, Nevada.
Read More